background
banner

EMLA 5% Price

Active Substance: Lidocaine, Prilocaine.

82
UAD , based on 7541 reviews.
View Drug details

Overview

Welcome to Dwaey, specifically on EMLA 5% Cream page.
This medicine contains an important and useful components, as it consists of Lidocaine, Prilocaine.
EMLA 5% is available in the market in concentration 25mg, 25mg/g and in the form of Cream.

ASPEN PHARMA TRADING LIMITED is the producer of EMLA 5% and it is imported from IRELAND, The most popular alternatives of EMLA 5% are listed downward .

Mode Of Action

Lidocaine and prilocaine are local anaesthetic agents of the amide type. Both work by stabilising the neuronal membranes and inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby giving rise to the anaesthetic action.

Indication

  • Local anaesthesia

Precaution

Caution when used over large areas and leaving on for >2 hr. Severe hepatic impairment. Caution when used in patients who are receiving class I and III antiarrhythmics. Dose reduction may be necessary in acutely ill, debilitated patients and elderly. Avoid using on open wounds or near the eyes. Pregnancy and lactation. Lactation: Excreted in breast milk; use not recommended

Side Effects

  • >10% Pallor/blanching (37%)
  • Application site erythema/pain (30%)
  • Genital mucous membrane burning sensation (17%)
  • Oral cavity
  • periodontal formulation (15%) 1-10% Alterations in temperature sensations (7%)
  • Application site edema (6-10%)
  • Itching (2%) <1% Rash
  • Myocardial dysfunction (rare)
  • Methemoglobinemia (rare)
  • Depression/excitation (rare)
  • Seizure (rare) Frequency Not Defined Localized discrete purpuric or petechial reactions (rare) Localized hyperpigmentation (rare) Allergic reactions (eg
  • urticaria
  • angioedema
  • bronchospasm
  • shock)

Contra indication

Neonates with gestational age <37 wk. Infants <12 mth of age who are receiving treatment with methaemoglobin-inducing agents or children who are receiving medications associated with drug-induced methaemoglobinemia. Children with congenital or idiopathic methaemoglobinemia. Application on mucous membranes, broken or inflamed skin.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Interaction

Increased risk of toxicity when used with drugs that are known to cause methaemoglobinaemia. Concurrent use with class III antiarrhythmics may lead to additive cardiac effects. Toxic effects may be additive when used with class I antiarrhythmics.

Alternatives Price List

  • XYLOCREAMUAD 41
  • XYLOCREAMUAD 41
  • PRILA 5%UAD 49
  • PRILA 5%UAD 49
  • EMLA 5%UAD 82

Releated Products

banner

Report Price Error

Please feel welcome to contact Us with any price or medical error. Our doctors will receive any reports.